These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34481963)

  • 1. Canagliflozin could improve the levels of renal oxygenation in newly diagnosed type 2 diabetes patients with normal renal function.
    Zhou S; Zhang Y; Wang T; Huang S; Gong S; Wang J; Yu P
    Diabetes Metab; 2021 Sep; 47(5):101274. PubMed ID: 34481963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol.
    Muller ME; Pruijm M; Bonny O; Burnier M; Zanchi A
    Adv Ther; 2018 Jun; 35(6):875-885. PubMed ID: 29802538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
    Pfeifer M; Townsend RR; Davies MJ; Vijapurkar U; Ren J
    Cardiovasc Diabetol; 2017 Feb; 16(1):29. PubMed ID: 28241822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
    N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
    Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
    Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
    Heerspink HJ; Desai M; Jardine M; Balis D; Meininger G; Perkovic V
    J Am Soc Nephrol; 2017 Jan; 28(1):368-375. PubMed ID: 27539604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal effects of canagliflozin in type 2 diabetes mellitus.
    Perkovic V; Jardine M; Vijapurkar U; Meininger G
    Curr Med Res Opin; 2015 Dec; 31(12):2219-31. PubMed ID: 26494163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial.
    Yamaguchi S; Shimabukuro M; Tanaka A; Imai T; Hiramitsu S; Takahashi N; Kadokami T; Ajioka M; Suzuki M; Node K;
    Diabetes Obes Metab; 2023 Feb; 25(2):354-364. PubMed ID: 36193841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
    Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D;
    Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
    Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
    Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; de Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V;
    J Am Soc Nephrol; 2020 May; 31(5):1128-1139. PubMed ID: 32354987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial.
    Tanaka A; Imai T; Shimabukuro M; Nakamura I; Matsunaga K; Ozaki Y; Minamino T; Sata M; Node K;
    J Diabetes Investig; 2022 Dec; 13(12):1990-1999. PubMed ID: 36114704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
    Weir MR; McCullough PA; Buse JB; Anderson J
    Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
    Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
    Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
    Davidson JA; Sloan L
    Adv Ther; 2017 Jan; 34(1):41-59. PubMed ID: 27854055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.
    Weir MR
    Postgrad Med; 2016; 128(3):290-8. PubMed ID: 26821720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canagliflozin: metabolic, cardiovascular and renal protection.
    Barrios V; Escobar C
    Future Cardiol; 2021 May; 17(3):443-458. PubMed ID: 33538620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.